USPTO Examiner COUNTS GARY W - Art Unit 1678

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18769708ASSAY METHOD OF ANTIBODYJuly 2024March 2025Allow810NoNo
18616550DETECTION OF ANTI-p53 ANTIBODIESMarch 2024January 2025Allow1010NoNo
18585679METHOD OF DETERMINING AN IMMUNOGENIC RESPONSE CHARACTERISTIC OF A CHEMICAL SUBSTANCEFebruary 2024March 2025Allow1320YesNo
18414339KITS AND METHODS TO DISTINGUISH FALSE LABOR AND TRUE LABORJanuary 2024December 2024Allow1120NoNo
18406399METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUSJanuary 2024April 2025Allow1520YesNo
18392925IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYSDecember 2023April 2025Abandon1510NoNo
18482286KITS AND METHODS FOR PREDICTION AND TREATMENT OF PREECLAMPSIAOctober 2023November 2024Allow1410YesNo
18467302ADRENOMEDULLIN ASSAYS AND METHODS FOR DETERMINING MATURE ANDRENDOMEDULLINSeptember 2023November 2024Allow1410YesNo
18367823METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUSSeptember 2023October 2023Allow110NoNo
18353683COMPOSITIONS AND METHODS FOR ASSAYING PLATELET REACTIVITY AND TREATMENT SELECTIONJuly 2023December 2024Allow1710YesNo
18340235ADRENOMEDULLIN ASSAYS AND METHODS FOR DETERMINING MATURE ANDRENDOMEDULLINJune 2023October 2024Allow1610YesNo
18330550METHODS OF DETECTING ANTI-LEPTIN NEUTRALIZING ANTIBODIESJune 2023May 2025Abandon2310YesNo
18315230SYSTEMS AND METHODS TO IDENTIFY AND TREAT SUBJECTS AT RISK FOR OBSTETRICAL COMPLICATIONSMay 2023January 2025Allow2011NoNo
18173604Type X Collagen Assays and Methods of Use ThereofFebruary 2023October 2024Abandon2010NoNo
18110229METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUSFebruary 2023July 2023Allow510NoNo
18164058HIGHLY SENSITIVE PARTICLE ENHANCED ASSAY FOR THE QUANTIFICATION OF NT-PROBNPFebruary 2023November 2024Abandon2210NoNo
18067622BIOMARKERS FOR DIAGNOSING IMPLANT RELATED RISK OF IMPLANT REVISION DUE TO ASEPTIC LOOSENINGDecember 2022July 2024Allow1910YesNo
17994029MARKER AND PRODUCT FOR AUXILIARY DIAGNOSIS OF VALVULAR HEART DISEASE (VHD)November 2022April 2024Abandon1721YesNo
18058683MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESSNovember 2022May 2025Abandon3020NoNo
17992664Analyte Test Strip Assays, and Test Strips and Kits for Use in Practicing the SameNovember 2022February 2025Abandon2711NoNo
18053028Immunoassay for Detecting Zika Virus InfectionNovember 2022September 2024Abandon2210NoNo
18049596ESTIMATING CELLULAR POPULATIONSOctober 2022January 2025Abandon2711NoNo
17970775METHODS FOR ANALYSING A URINE SAMPLEOctober 2022March 2025Abandon2811NoNo
17962125SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUIDOctober 2022April 2025Allow3021YesNo
17957853COMPOSITIONS AND METHODS TO DETECT GASTROINTESTINAL DISEASESeptember 2022December 2024Allow2720NoNo
17822475ENCAPSULATED REAGENTS AND METHODS OF USEAugust 2022July 2024Allow2311NoNo
17897026METHOD AND DEVICE FOR DISCRIMINATING BETWEEN VIRAL AND BACTERIAL INFECTIONSAugust 2022March 2025Allow3020NoNo
17870477METHODS AND MATERIALS FOR IDENTIFYING AND TREATING AUTOIMMUNE GFAP ASTROCYTOPATHYJuly 2022June 2024Allow2310YesNo
17812537BIOMARKERS FOR DIAGNOSING IMPLANT RELATED RISK OF IMPLANT REVISION DUE TO ASEPTIC LOOSENINGJuly 2022September 2024Allow2621NoNo
17851613Secreted P-glycoprotein is a Non-Invasive Biomarker of Chronic RhinosinusitisJune 2022February 2025Abandon3121NoNo
17848804ASSAY TO DETECT AND QUANTITATE SPECIFIC ANTIBODIES FOR VARIOUS REDOX FORMS OF HMGB1June 2022June 2024Allow2410NoNo
17824162DETECTION REAGENT AND THERAPEUTIC TARGET FOR B CELL TUMOR AFTER TARGETED THERAPY AND RELATED APPLICATIONMay 2022January 2024Allow1910NoNo
17745140GLUCURONYLATION AS A NEW ACIDIC POST-TRANSLATIONAL MODIFICATION ON THERAPEUTIC MONOCLONAL ANTIBODIESMay 2022April 2024Abandon2301NoNo
17743289METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUSMay 2022April 2024Abandon2310NoNo
17735524COMPOSITIONS AND METHODS FOR THE DETECTION OF HOST CELL PROTEINSMay 2022September 2024Allow2820NoNo
17730403DETECTION OF ANTI-p53 ANTIBODIESApril 2022December 2023Allow2020NoNo
17715294METHODS AND DEVICES FOR QUANTITATIVELY ESTIMATING SYNDECAN-1April 2022August 2024Allow2820YesYes
17699706Methods of Detecting Anti-folic acid Antibodies and Uses ThereofMarch 2022February 2024Allow2311YesNo
17762088METHOD FOR ASSIGNING ANTIBODY STANDARD AND DETERMINING MINIMUM DETECTION LIMIT OF ANTIBODY DETECTION REAGENTMarch 2022February 2023Allow1010NoNo
17695381Biomarker Panel for Non-Invasive Diagnosis of Congenital Renal DysfunctionMarch 2022November 2023Allow2011YesNo
17693789MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILUREMarch 2022November 2023Abandon2001NoNo
17684296MULTIPLEXED DIAGNOSTIC TO RECOGNIZE CONCENTRATIONS OF RELATED PROTEINS AND PEPTIDESMarch 2022December 2023Abandon2210NoNo
17679493METHOD AND COMPOSITION FOR DETECTION OF PROTEOLYTIC PRODUCTS AND DIAGNOSIS OF MALIGNANT NEOPLASTIC DISEASEFebruary 2022May 2024Allow2621YesNo
17679640CATION EXCHANGE CHROMATOGRAPHY METHODSFebruary 2022July 2024Allow2930NoNo
17676072NOVEL TARGETS FOR THE TREATMENT AND DIAGNOSIS OF PATIENTS WITH ATHEROSCLEROSIS AND ENHANCED RISK OF END ORGAN DAMAGEFebruary 2022January 2024Abandon2311NoNo
17668261DETECTION OF GLUCURONIDATED AND 3-BROMOTYROSINEFebruary 2022May 2024Allow2720NoNo
17667376METHODS FOR DETERMINING AMOUNT OF FUNCTIONAL ALBUMINFebruary 2022October 2023Allow2110NoNo
17590325LATERAL FLOW TEST STRIP READERS, CARTRIDGES AND RELATED METHODSFebruary 2022June 2025Allow4141YesNo
17558248KITS AND METHODS FOR PREDICTION AND TREATMENT OF PREECLAMPSIADecember 2021May 2023Allow1710NoNo
17534012ASSAYS FOR DETECTING THE PRESENCE OR AMOUNT OF AN ANTI-DRUG ANTIBODYNovember 2021November 2023Allow2301YesNo
17525717KITS AND METHODS TO DISTINGUISH FALSE LABOR AND TRUE LABORNovember 2021October 2023Allow2310YesNo
17508619ASSAY METHOD FOR THE DETECTION OF VCAM-1 AND ALPHA-2-MACROGLOBULIN IN BLOODOctober 2021April 2023Allow1831YesNo
17490568HIGHLY SENSITIVE PARTICLE ENHANCED ASSAY FOR THE QUANTIFICATION OF NT-PROBNPSeptember 2021November 2022Allow1321NoNo
17473747METHODS FOR DETERMINING THERAPEUTIC RESPONSIVENESS FOR INFLAMMATORY BOWEL DISEASE THERAPYSeptember 2021March 2025Allow4211NoNo
17470485ANTI-CARBAMYLATED PROTEIN ANTIBODIES AND THE RISK FOR ARTHRITISSeptember 2021September 2023Abandon2401NoNo
17462209USE OF MAGNETIC NANOPARTICLES FOR THE DETECTION AND QUANTITATION OF ANALYTE(S)August 2021October 2022Allow1421YesNo
17411863GDF15 IN GLAUCOMA AND METHODS OF USE THEREOFAugust 2021November 2023Allow2611YesNo
17408096DETECTING ADAPTIVE IMMUNITY TO CORONAVIRUSAugust 2021February 2023Abandon1821NoNo
17428416COMPOSITIONS AND METHODS TO DETECT GASTROINTESTINAL DISEASEAugust 2021November 2023Allow2820YesNo
17376058COMPOSITIONS AND METHODS FOR ASSAYING NEUTRALIZING ANTIBODIESJuly 2021March 2024Allow3211NoNo
17371025Device and MethodsJuly 2021September 2024Allow3841YesNo
17367049COMPOSITIONS AND METHODS FOR PURIFICATION AND DETECTION OF HDL AND APOAIJuly 2021April 2024Allow3430NoNo
17353532ERYTHROCYTE SIMULATING PARTICLE, PREPARATION METHOD THEREFOR, AND QUALITY CONTROL OR CALIBRATOR CONTAINING SAMEJune 2021April 2025Allow4611NoNo
17349134ADRENOMEDULLIN ASSAYS AND METHODS FOR DETERMINING MATURE ADRENOMEDULLINJune 2021March 2023Allow2110NoNo
17292109METHODS AND SYSTEMS FOR TREATING CANCER BASED ON RESPONSE PREDICTION USING LIGHT SCATTERING TECHNOLOGYMay 2021October 2024Allow4101YesNo
17290369FACTOR XIII IMMUNOASSAYApril 2021October 2024Allow4110NoNo
17288542MEANS AND METHOD FOR POINT-OF-CARE ANALYSIS OF LIQUID SAMPLESApril 2021March 2025Abandon4701NoNo
17286221Biomarkers For A Systemic Lupus Erythematosus (SLE) Disease Activity Immune Index That Characterizes Disease ActivityApril 2021June 2025Abandon5021NoNo
17231209METHOD FOR ASSISTING PREDICTION OF EXACERBATION OF RESPIRATORY INFECTION, AND DEVICE TO ASSIST IN PREDICTING EXACERBATION OF RESPIRATORY INFECTIONApril 2021July 2024Allow3921YesNo
17212360System and Method for Disease Surveillance and Disease Severity Monitoring for COVID-19March 2021June 2024Abandon3901NoNo
17190135RGMa Fragment Based Diagnostic AssayMarch 2021June 2023Abandon2810NoNo
17268337METHOD FOR MEASURING THE TRIMETHYLAMINE N-OXIDE PRODUCTION CAPACITY IN AN INDIVIDUALFebruary 2021May 2025Allow5111NoNo
17265393METHODS FOR DETECTING ANTI-DRUG ANTIBODIESFebruary 2021April 2025Allow5011YesNo
17127402BEAD-BASED ASSAYS FOR PROTEIN ANALYSISDecember 2020February 2024Allow3821NoNo
17056889PARAMAGNETIC IMMUNOBEADS FOR THE ISOLATION OF HUMAN ADIPOSE-DERIVED STEM CELLSNovember 2020February 2025Allow5130NoNo
17055705METHODS FOR DETECTING PROSTATE CANCER PATHOLOGY ASSOCIATED WITH ADVERSE OUTCOMESNovember 2020December 2024Abandon4911NoNo
17097688Bio-Fet Sensor Array with Matrix Controlled On-Chip ElectrodeNovember 2020September 2024Abandon4601NoNo
17054820BLOOD BIOMARKERS OF STROKENovember 2020November 2024Allow4821NoNo
17093461BIOCHEMICAL PREDICTORS OF RED BLOOD CELL QUALITYNovember 2020September 2023Allow3410YesNo
17088237METHODS OF SCREENING FOR SORTILIN BINDING ANTAGONISTSNovember 2020September 2024Allow4730YesNo
17087103MONOCLONAL ANTIBODIES SPECIFICALLY FOR THE ANTIGEN P OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS, PRODUCED AND SECRETED BY THE CELLS HYBRIDOMAS, USEFUL FOR DETECTION AND DIAGNOSTIC OF THE INFECTION CAUSED BY RSVNovember 2020September 2023Allow3400YesNo
16641951MEANS AND METHOD FOR DETECTING ANALYTES BY MEANS OF MACROSCOPIC GRANULATE PARTICLESOctober 2020December 2024Abandon5731YesNo
17080533PLASMA THERMOGRAMS FOR DIAGNOSIS AND TREATMENT OF ACUTE MYOCARDIAL INFARCTIONOctober 2020July 2023Allow3311YesNo
17075470Method, Systems, and a Kit for Detection, Diagnosis, Monitoring and Treatment of COVID-19October 2020February 2023Abandon2841YesNo
17046984SCREENING ASSAYS AND KITS FOR CHARACTERIZING AN ABILITY OF A CANDIDATE COMPOUND TO MODULATE A BINDING AFFINITY BETWEEN AN FBW7 PROTEIN AND AN FBW7 SUBSTRATEOctober 2020July 2024Abandon4501NoNo
17065631METHOD AND APPARATUS FOR MONITORING THE STATE OF HEALTH OF DAIRY COWSOctober 2020September 2023Abandon3611NoNo
17063673METHOD OF DETERMINING COMPOSITION EFFECTIVE FOR TREATING DIABETESOctober 2020May 2023Allow3121NoNo
17036739METHOD OF DIAGNOSING HEART MUSCLE DAMAGESeptember 2020January 2025Abandon5221NoNo
16975482BIOMARKERS FOR UROLOGIC CHRONIC PELVIC PAIN SYNDROMEAugust 2020April 2024Abandon4301NoNo
16971705COMPOUNDS AND METHODS FOR THE DETECTION OF FABRY DISEASEAugust 2020July 2024Abandon4711NoNo
16971286QUANTITATIVE ANALYSIS OF PROTEINSAugust 2020January 2025Allow5320YesNo
16996281METHODS OF DETECTING ANTI-LEPTIN NEUTRALIZING ANTIBODIESAugust 2020March 2023Allow3001YesNo
16918911METHOD FOR RE-USING TEST PROBE AND REAGENTS IN AN IMMUNOASSAYJuly 2020January 2024Abandon4311NoNo
16954918ANGPTL8 ASSAY AND USES THEREOFJune 2020February 2024Allow4411NoNo
16954935Detection of Autoantibodies for Diagnosing Degenerative Diseases of the Skeletal SystemJune 2020November 2022Allow2910YesNo
16946328Method and products for the diagnosis of a seafood allergyJune 2020September 2022Allow2711YesNo
16899629CIRCULATING ANGIOPOIETIN-2 (ANG-2) AND INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 7 (IGFBP7) FOR THE PREDICTION OF STROKEJune 2020May 2023Allow3531YesNo
16771413LABEL-FREE OPTICAL DETECTION IN CAPTURE ZONES IMMOBILIZED ON STRIPS FOR LATERAL FLOW ASSAYSJune 2020August 2024Allow5021YesNo
16888252SYNTHETIC CONTROLS FOR IMMUNOHISTOCHEMISTRYMay 2020February 2024Allow4411NoNo
16766337METHOD AND DEVICE FOR DISCRIMINATING BETWEEN VIRAL AND BACTERIAL INFECTIONSMay 2020November 2022Abandon3031YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COUNTS, GARY W.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
6
(85.7%)
Examiner Reversed
1
(14.3%)
Reversal Percentile
24.3%
Lower than average

What This Means

With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
44
Allowed After Appeal Filing
6
(13.6%)
Not Allowed After Appeal Filing
38
(86.4%)
Filing Benefit Percentile
13.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner COUNTS, GARY W - Prosecution Strategy Guide

Executive Summary

Examiner COUNTS, GARY W works in Art Unit 1678 and has examined 455 patent applications in our dataset. With an allowance rate of 66.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner COUNTS, GARY W's allowance rate of 66.6% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by COUNTS, GARY W receive 2.17 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by COUNTS, GARY W is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +32.8% benefit to allowance rate for applications examined by COUNTS, GARY W. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.6% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 27.0% of cases where such amendments are filed. This entry rate is in the 29% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 78.8% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 84.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.1% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.3% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.